Clinical trial NCT02187848: Evaluation of SAR408701 in Patients With Advanced Solid Tumors
Official title: A First-in-Human Study for the Evaluation of the Safety, Pharmacokinetics and Antitumor Activity of SAR408701 in Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Neoplasm Malignant
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2014-07-11
Enrollment: 254
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Primary Objectives:

* To determine the maximum tolerated dose (MTD) of SAR408701 administered as monotherapy, once every 2 weeks (with and without a loading dose at Cycle 1) to patients with advanced solid tumors (Main Escalation and Loading Dose Escalation Q2W).
* To determine the maximum tolerated dose (MTD) of SAR408701 administered as monotherapy, once every 3 weeks to patients with advanced solid tumors (Escalation Q3W Cycle).
* To assess efficacy according to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) (Expansion Phase) when SAR408701 is administered once every 2 weeks with or without a loading dose at Cycle 1.

Secondary Objectives:

* To characterize the overall safety profile of SAR408701.
* To characterize the pharmacokinetic (PK) profile of SAR408701 and of its potential circulating derivatives.
* To identify the recommended phase 2 dose (RP2D) of SAR408701.
* To assess the potential immunogenicity of SAR408701.

Detailed description: The study duration for an individual patient will start from the signature of the informed consent, will include a period to assess eligibility (screening period) of up to approximately 4 weeks (28 days), a treatment period and an end-of-treatment visit around 30 days following the last administration of study drug, and at least one follow-up visit after the end-of-treatment visit. Additional follow-up visits may be required until resolution or stabilization of adverse events (at least 30 days). Treatment may continue until precluded by toxicity, progression, or upon patient's request. If the patient stops study treatment for reason other than disease progression, follow-up visit will be performed every 3 months until disease progression or initiation of another anti-tumor treatment or death, whichever comes first.

Eligibility criteria: Inclusion criteria:

* Locally advanced or metastatic solid malignant tumor disease for which no standard alternative therapy is available.
* Availability of archived tumor tissue for carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5 or CEA) testing.
* For participants in the Dose Escalation Cohorts (Main Escalation and Loading Dose Cohorts at every 2 week cycle and Dose Escalation every 3 week cycle): patients with tumors expressing or likely to be expressing CEACAM5 which includes colorectal cancer (CRC), non-squamous non-small cell lung cancer (NSCLC), gastric adenocarcinoma, squamous cell carcinoma of the cervix, pancreas adenocarcinoma, bladder transitional cell carcinoma, cholangiocarcinoma, epithelial ovarian cancer and endometrial adenocarcinoma are favored, or if carcinoembryonic antigen (CEA) plasma levels \>5 ng/mL.
* For participants to the Expansion Phase cohorts: patients with CRC or with CEACAM5 positive non-squamous NSCLC, small cell lung cancer (SCLC) or gastric carcinoma (including esophago-gastric junction adenocarcinoma of the Siewert types II and III).
* At least one measurable lesion by RECIST v1.1 in the Expansion Phase only.
* At least one lesion amenable to biopsy (Expansion cohort - CRC and gastric cancer only). Patient must consent to a baseline biopsy for retrospective confirmation of tumor CEACAM5 expression, except if NSCLC or SCLC without lesion amenable to biopsy.
* Signed informed consent.

Exclusion criteria:

* Aged less than 18 years.
* Eastern Cooperative Oncology Group (ECOG) performance status more than 1.
* New or progressing brain involvement.
* Concurrent treatment with any other anticancer therapy or inadequate wash-out period for prior anticancer therapies before first administration of SAR408701, or non-resolution of toxicities induced by these anticancer therapies.
* Female or male patients with reproductive potential who do not agree to use an accepted effective method of contraception during the study treatment period and for at least 3 months following completion of study treatment.
* Pregnancy or breast-feeding.
* Participation to any clinical research study evaluating another investigational drug or therapy within 3 weeks of initiation of study regimen.
* Prior therapy targeting CEACAM5.
* Prior maytansinoid treatments (DM1 or DM4 antibody drug conjugates).
* Poor bone marrow reserve resulting in low blood cell counts.
* Poor kidney and liver functions.
* Any of the following within 6 months prior to study enrolment: infectious or inflammatory bowel disease, diverticulitis, gastrointestinal perforation, intestinal obstruction, and gastrointestinal hemorrhage. Patients with malabsorption syndrome are excluded.
* Previous history and or unresolved corneal disorders. The use of contact lenses is not permitted.
* Unresolved signs and symptoms of neuropathy; Grade 1 is acceptable if prior neurotoxic drugs such as cisplatin or taxanes.
* Abnormal cardiac function defined by a left ventricular ejection fraction (LVEF) of \<50%.
* Cardiac conduction defects, or any other clinically significant arrhythmias.
* Known intolerance to infused protein products.
* Medical conditions requiring concomitant administration of medications with narrow therapeutic window, metabolized by cytochrome P450 (CYPs) enzymes and for which a dose reduction cannot be considered.
* Medical conditions requiring concomitant administration of strong CYP3A inhibitor, unless it can be discontinued at least 2 weeks before 1st administration of SAR408701.
* Contraindications to the use of ophthalmic vasoconstrictor and/or corticosteroid as per package insert of each drug, including the following: increase intraocular pressure, prior or current glaucoma, narrow-angle glaucoma, ongoing eye infection, uncontrolled hypertension, known/suspected allergy to constituents of the preparation (such as sodium bisulfite).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: Number of dose limiting adverse events (every 2 week cycle)
timeFrame: 4 weeks
measure: Assessment of overall response rate using standard imaging and RECIST 1.1 criteria
timeFrame: Up to 40 months
measure: Number of dose limiting adverse events (every 3 week cycle)
timeFrame: 3 weeks
Secondary outcomes:
measure: Number of treatment emergent adverse events
timeFrame: Up to 4 years
measure: Maximum concentration (Cmax)
timeFrame: 2 months
measure: Time to reach maximum concentration (tmax)
timeFrame: 2 months
measure: Trough plasma concentrations (Ctrough)
timeFrame: Intensive testing within first 2 months, then every 2 weeks
measure: Area under the plasma concentration versus time curve between 0 and 14 days (AUC0-14day) for Q2W or between 0 and 21 days (AUC-21 day) for Q3W
timeFrame: 2 months
measure: Mean systemic clearance (CL)
timeFrame: 2 months
measure: Clearance at steady state (CLss)
timeFrame: 2 months
measure: Accumulation ratio (Rac) on AUC0-14day and Cmax
timeFrame: 2 months
measure: Detection of the development of anti-SAR408701 antibody
timeFrame: Up to 40 months
measure: Duration of response
timeFrame: Up to 40 months - assessment every 6-8 weeks
measure: Time to Progression
timeFrame: Up to 40 months - assessment every 6-8 weeks
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale University School of Medicine Site Number : 840002
state: Connecticut
city: Boston
country: United States
facility: Dana Farber Cancer Institute- Site Number : 840005
state: Massachusetts
city: Toronto
country: Canada
facility: Investigational Site Number : 124001
state: Ontario
city: Bordeaux Cedex
country: France
facility: Investigational Site Number : 250003
city: Dijon
country: France
facility: Investigational Site Number : 250006
city: Marseille
country: France
facility: Investigational Site Number : 250004
city: Rennes
country: France
facility: Investigational Site Number : 250007
city: Saint Mande
country: France
facility: Investigational Site Number : 250005
city: TOULOUSE Cedex 9
country: France
facility: Investigational Site Number : 250002
city: Villejuif
country: France
facility: Investigational Site Number : 250001
city: Seoul
country: Korea, Republic of
facility: Investigational Site Number : 410002
state: Seoul-teukbyeolsi
city: Seoul
country: Korea, Republic of
facility: Investigational Site Number : 410005
state: Seoul-teukbyeolsi
city: Seoul
country: Korea, Republic of
facility: Investigational Site Number : 410003
state: Seoul-teukbyeolsi
city: Seoul
country: Korea, Republic of
facility: Investigational Site Number : 410004
state: Seoul-teukbyeolsi
city: Seoul
country: Korea, Republic of
facility: Investigational Site Number : 410001
state: Seoul-teukbyeolsi
city: Barcelona
country: Spain
facility: Investigational Site Number : 724001
state: Barcelona [Barcelona]
city: Madrid / Madrid
country: Spain
facility: Investigational Site Number : 724004
state: Madrid, Comunidad De
city: Madrid
country: Spain
facility: Investigational Site Number : 724003
state: Madrid, Comunidad De
city: Majadahonda
country: Spain
facility: Investigational Site Number : 724002
state: Madrid
city: Madrid
country: Spain
facility: Investigational Site Number : 724006
Study officials:
affiliation: Sanofi
name: Clinical Sciences & Operations
role: STUDY_DIRECTOR
References:
citation: Gazzah A, Bedard PL, Hierro C, Kang YK, Abdul Razak A, Ryu MH, Demers B, Fagniez N, Henry C, Hospitel M, Soria JC, Tabernero J. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022 Apr;33(4):416-425. doi: 10.1016/j.annonc.2021.12.012. Epub 2022 Jan 10.
citation: Tabernero J, Bedard PL, Bang YJ, Vieito M, Ryu MH, Fagniez N, Chadjaa M, Soufflet C, Masson N, Gazzah A. Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens. Cancer Res Commun. 2023 Aug 28;3(8):1662-1671. doi: 10.1158/2767-9764.CRC-23-0284. eCollection 2023 Aug.